Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
This article was originally published in The Pink Sheet Daily
Piramal Healthcare Chairman Ajay Piramal talks about the Indian pharmaceutical market after selling his domestic branded generics business to Abbott.
You may also be interested in...
Taking A Deep Breath: Novartis & Schering Split Respiratory Product Rights, Giving Novartis Indacaterol
Novartis is building a respiratory franchise based around its promising chronic obstructive pulmonary disease drug QAB149 (indacaterol) and is taking steps to make sure the world knows it
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.